




# European Reference Network

for rare or low prevalence  
complex diseases

## Network

Vascular Diseases  
(VASCERN)



# Arteriovenous malformations

## VASCERN VASCA working group Members:

Julien Coulie, Rune Andersen, Maria Barea, Eulalia Baselga Torres, Miguel Bejarano Serrano, Sigurd Berger, Annouk Anne Bisdorff, Olivia Boccara, Petra Borgards, Jasmine Borg Tahri, Maria Bom Sucesso, Laurence M Boon, Claudia Carnevale, Veronica Celis Passini, Anca Maria Cimpean, Vittorio Civelli, Chantal Cotter, Andrea Diociaiuti, Veronika Dvorakova, May El Hachem, Christina Flucher, Sofia Frisk, Nader Ghaffarpour, Paolo Gasparella, Emir Haxhija, Annegret Holm, Alan D Irvine, Mikkel Kaltoft, Friedrich G Kapp, Olga Koskova, Kristiina Kyrklund, Antonio Miguel Madureira, Darius Palionis, Przemysław Przewratil, Hannele Salonen, Bitten Schönewolf-Greulich, Maria-Corina Stanciulescu, Jaroslav Štěřba, Jukka Tolonen, Birute Vaisnyte, Carine van der Vleuten, Dariusz Wyrzykowski, Leo Schultze Kool, Miikka Vikkula.

## Cooperating Guests:


Georges Rodesch

# Disclaimer

- This document is an opinion statement reflecting strategies proposed by experts and patient representatives involved in the Vascular Anomalies (VASCA) Rare Disease Working Group of VASCERN.
- It is preferable that patients be evaluated in a multidisciplinary center specialized in the diagnosis and management of vascular anomalies.
- This pathway is issued on **February 20, 2026** and will be further validated and adjusted as needed.
- Responsibility for care of individual patients remains with the treating physician.
- Multidisciplinary team should re-evaluate treatment decisions regularly.




## Arteriovenous Malformation (AVM)





# Arteriovenous Malformation (AVM)


## Clinical symptoms & work-up





# Arteriovenous Malformation (AVM): Associated symptoms

## Hereditary Syndromic AVM



\* Parkes-Weber Syndrome :

- Hereditary or sporadic
  - Hereditary caused by germline RASA1 or EPHB4 mutations
  - Somatic caused by mosaic RASA1 or KRAS mutations
- Clinical presentation :
  - Limb (lower>upper) hypertrophy
  - Diffuse erythema and warmth
  - "CM" (faint red stain (blush)) on affected limb
  - Multiple arteriolo-venular shunts

*HHT : Hereditary Hemorrhagic Telangiectasia or Osler-Weber-Rendu syndrome*  
*CM-AVM : Capillary Malformation - Arteriovenous Malformation*  
*PHTS : PTEN Hamartoma Tumor Syndrome*

LEGEND:

Clinical evaluation


Investigations

Genes



# Arteriovenous Malformation (AVM): Associated symptoms

## Sporadic vs Syndromic AVMs



**CLOVES** : Congenital Lipomatous Overgrowth, Vascular Malformations, Epidermal Nevi, and Skeletal/Scoliosis Anomalies

LEGEND:

Clinical evaluation


Investigations

Genes



# Arteriovenous Malformation (AVM): Associated symptoms

## Sporadic Non-syndromic AVMs



LEGEND:

Clinical evaluation

Investigations


Genes





# Arteriovenous Malformation (AVM): Management/Treatment

## Non-syndromic AVMs





European  
Reference  
Network

**VASCERN**

Gathering the best expertise in Europe  
to provide accessible cross-border healthcare  
to patients with rare vascular diseases



VASCERN, the European Reference Network on Rare Multisystemic Vascular Diseases, is dedicated to gathering the best expertise in Europe in order to provide accessible cross-border healthcare to patients with rare vascular diseases (an estimated 1.3 million concerned). These include arterial diseases (affecting aorta to small arteries), arterio-venous anomalies, vascular malformations, and lymphatic diseases.

VASCERN currently gathers 48 expert teams from 39 highly specialized multidisciplinary HCPs, plus 6 additional Affiliated Partner centers, coming from 19 EU Member States, as well as various European Patient Organisations, and is coordinated in Paris, France.

Through our 6 Rare Disease Working Groups (RDWGs) as well as several thematic WGs and the ePAG (European Patient Advocacy Group), we aim to improve care, promote best practices and guidelines, reinforce research, empower patients, provide training for healthcare professionals and realise the full potential of European cooperation for specialised healthcare by exploiting the latest innovations in medical science and health technologies.

More information available at: [www.vascern.eu](http://www.vascern.eu)

Follow us on     **YouTube**



**Funded by  
the European Union**